Safety and potential improvement of autologous fat-derived stem cells for adult facial atrophic scars
Official title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Split-Face, Phase 1/2 Study to Evaluate the Safety and Efficacy of a Single Administration of TRTP-101 in Adults With Atrophic Scars
Run by CellinCells · NCT07474467 · Data updated 2026-11-12
This study tests whether a single treatment with TRTP-101, made from the patient’s own fat-derived stem cells, is safe and may improve facial acne-related atrophic scars in adults.
Quick facts
| Phase | Phase1; Phase2 |
|---|---|
| Study type | Interventional |
| Ages | 19 Years and up |
| Sex | All |
| Enrollment | 31 (estimated) |
| Sponsor | CellinCells Industry-sponsored |
| Drugs / interventions | radiation |
| Locations | 1 site (Seoul) |
| Status | Recruiting |
| Started | August 12, 2026 |
| Main results expected | February 1, 2029 |
| Study ends | August 1, 2029 |
| Registry record updated | August 20, 2026 |
| Trial ID | NCT07474467 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults over 19 years with atrophic facial scars, particularly acne scars, and a dissatisfaction score indicating desire for improvement.
✕Probably not a fit
Individuals without atrophic facial scars or those with contraindicated conditions or recent conflicting treatments may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This interventional study first aims to determine dose-limiting toxicity after a single administration of TRTP-101 to multiple atrophic scar sites. In a subsequent phase, a placebo-controlled, split-face design will compare TRTP-101 to placebo on cheeks or temple areas, assessing safety and scar improvement. Eligible participants are adults over 19 with atrophic facial scars, including acne scars, and a dissatisfaction with current appearance. The trial excludes individuals with prior cell therapy, recent dermal procedures, infections in the scar area, coagulation disorders, or immunosuppressive treatments. The lead sponsor is CellinCells, with Samsung Medical Center as the site in Seoul, Korea.
Why it matters
Potential benefit: If successful, participants could see reduced scar appearance and improved self-image from a treatment that uses their own cells.
How similar studies have gone: Earlier approaches using autologous cell-based therapies for skin repair have shown safety signals and potential cosmetic benefits in limited settings; this trial extends to TRTP-101 with a rigorous split-face design.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male or Female aged greater than 19 years * Acne scars graded ≥ 3 on the 5-point ASRS \[Phase 1\] * Four or more atrophic scars in the joints, genitals, perineum, and face except for the lips, eyes and nose \[Phase 2\] * Atrophic scar lesions approximately 2 cm in diameter located on the cheeks or temple on both sides of the face * A response of "dissatisfied" or worse on the Subject Acne Scar Self-Assessment Scale Exclusion Criteria: * History of cell therapy * Treatment of Dermal resurfacing, Chemical/Mechanical Peel and Skin Photorejuvenation * Treatment of Hyaluronic acid/collagen skin filler, non-permanent soft tissue filler and fat grafting * Positive for virus infection * Use of Anticoagulant therapy or NSAIDs * Thrombocytopenia or other coagulation disorder * History of keloid scars * Infectious disease or other dermatitis in the area of the atrophic scar * Use of Immunosuppressant, immunomodulating drug, anticancer drug or radiation therapy * Use of systemic steroid medication * History of hypersensitivity or severe allergic reactions (e.g., anaphylaxis, Guillain-Barre syndrome, etc.) * Use of retinoid medications
Where it's running
-
Samsung Medical Center
Seoul, South Korea Recruiting
Study contacts
- Principal investigator: Jonghee Lee, MD — Samsung Medical Center
- Study coordinator: HyeJung Park
- Email: hjpark@cellincells.com
- Phone: +82-70-4469-9115
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Long-term follow-up after TRTP-101 treatment for scar
This study checks in with people who previously received TRTP-101 to see if the treatment remains safe and helps with atrophic scar over several years.
-
Exosome injections to improve atrophic facial scars
This trial will test whether injecting exosomes into atrophic facial scars improves their appearance and texture compared with saline injections in adults with multiple facial scars.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.